On August 3, 2026, Kura Oncology, a biopharmaceutical company based in San Diego, announced that it had awarded six new employees stock options as part of their hiring inducement. A total of 104,500 shares of common stock were distributed under the company’s 2023 Inducement Option Plan, approved by the Compensation Committee of the company’s board.
Each stock option was set at an exercise price of $9.19 per share, reflecting the stock’s closing price on the date of the grant. The employees will not immediately gain full access to their shares. Instead, the shares will vest in stages: 25% will become available after one year. The remaining 75% will vest monthly over the following 36 months, provided the employees remain with the company during that time.
The Compensation Committee designed the stock options in compliance with Nasdaq Listing Rule 5635(c)(4), which allows companies to offer inducement awards to new hires. Kura, which focuses on precision medicines for cancer treatment, is expanding its workforce to support the commercialization of KOMZIFTI, an FDA-approved drug for certain types of blood cancer. The grants are governed by the terms of the 2023 Inducement Option Plan and individual agreements.
Kura’s efforts to attract top talent align with its ongoing mission to develop innovative therapies for hematologic malignancies and solid tumors. The company continues to pioneer advancements in targeted cancer treatments, including work in menin inhibition and farnesyl transferase inhibition. Additional information about Kura Oncology can be found on its website, and the company maintains a presence on X and LinkedIn.